Protein-protein interactions as new drug targets

Protein-protein interactions as new drug targets Download PDF EPUB FB2

Drugs targeting such interactions are likely to act with fewer side effects than conventional medication influencing whole cell functions. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein : Hardcover.

Disease-relevant intracellular protein-protein interactions occurring at defined cellular sites possess great potential as drug targets. They permit highly specific pharmacological interference with defined cellular functions. Protein Interactions as Targets in Drug Discovery, Volumeis dedicated to the design of therapeutics, both experimental and computational, that target protein interactions.

Chapters in this new release include Trends in structure based drug design with protein targets, From fragment- to peptide-protein interaction: addressing the structural basis of binding using Supervised Molecular Dynamics (SuMD), Protein-protein and protein-ligand interactions.

Drugs targeting such interactions are likely to act with fewer side effects than conventional medication influencing whole cell functions. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein interactions.

Protein-Protein Interactions as Drug Targets. Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.

Kurt Deshayes, Jeremy Murray, Domagoj Vucic The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer. Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation.

This book comprehensively reviews the state-of-the-art strategies developed for protein-protein interaction (PPI) inhibitors, and highlights the success stories in new drug discovery and development. Consisting of two parts with twelve chapters, it demonstrates the design strategies and case studies of small molecule PPI inhibitors.

Protein–protein interactions as drug targets. Modulation of protein–protein interactions (PPIs) is becoming increasingly important in drug discovery and chemical biology. While a few years ago this ‘target class’ was deemed to be largely undruggable an impressing number of publications and success stories now show that targeting PPIs with small, drug-like molecules indeed.

Protein-Protein Interactions as Potential Targets of Drug Designing Zeeshan Zahoor Banday1; Ghulam Md Ashraf * 1School of Life Sciences, Jawaharlal Nehru University, New Delhi, India *Correspondence to: Ghulam Md Ashraf, King Fahd Medical Research Center, King Abdulaziz University, P.

BoxJeddahSaudi Arabia. Tel: + ; E-mail: @. Protein–protein interactions (PPIs) recently have been recognized as a major class of drug targets. Many of the successful “classical” biotechnology protein drugs are agonists or antagonists of PPIs and there are established pathways for their : Alexander Dömling.

Sickness-associated intracellular protein-protein interactions occurring at outlined cellular websites possess good potential as drug targets. They permit. Handb Exp Pharmacol. ;():v-vi. Protein-protein interactions as new drug targets. Preface. Klussmann E, Rosenthal W. PMID: Cited by: 2.

This book comprehensively reviews the state-of-the-art strategies developed for protein-protein interaction (PPI) inhibitors, and highlights the success stories in new drug discovery and development. Consisting of two parts with twelve chapters, it demonstrates the design strategies and case studies of small molecule PPI : Chunquan Sheng, Gunda I.

Georg. interaction modulators. Modern drug discovery is molecular target driven with the aim of identifying new thera-peutic agents that can selectively target disease-specific molecular mechanisms or pathways.

In this context, protein–protein (PP) interactions (PPIs) are an attractive emerging class of molecu-lar targets. Critical cellular. Protein–protein interactions (PPIs) are increasingly being targeted by drug discovery groups, and there exists great scope for therapeutic modulation of this target class in by: Modulation of protein-protein interactions (PPIs) is becoming increasingly important in drug discovery and chemical biology.

While a few years ago this 'target class' was deemed to be largely. Introduction. The classification of protein–protein interactions (PPI) as druggable targets is relatively new. If one considers druggability as the ability to modulate the therapeutic target with a small orally available molecule [], the first review that included small molecules as antagonists of PPI dates from [].However, progress was initially slowed by a focus on discovery tools Cited by: ISBN: OCLC Number: Description: xv, pages: illustrations: Contents: PART I: ORGANIZATION OF SCAFFOLDS --A-Kinase Anchoring Proteins as the Basis for cAMP Signaling / K.L.

Dodge-Kafka, A. Bauman, and M.S. Kapiloff --Arrestins as Multi-Functional Signaling Adaptors / V.V. Gurevich, E.V. Gurevich, and W.M. This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein interactions.

Introduction: targeting protein–protein interactions. Pharmaceutical R&D undergoes a decline of productivity as the number of new drugs approved by the FDA regularly decreases.

Besides market forces and difficulties such as demand and competition. Protein–protein interactions (PPIs) control a large number of biological processes. An attempt to design novel drug molecules has led to an increasing interest in the protein surfaces.

However, a new type of intracellular drug target—Protein-Protein Interactions (PPIs)—are now expanding the space in which to search for new types of medicines.

PPIs are protein complexes inside the cell that play regulatory or structural roles.Such protein-protein interaction (PPI) complexes can be considered a type of drug target. PPI targets are different from traditional drug targets that comprise of a single protein, more specifically an enzyme, whose function is targeted for reduction by a chemical inhibitor.